PTH-099 A novel approach to the implementation of biosimilar infliximab ct-p13 for the treatment of ibd utilising therapeutic drug monitoring: the edinburgh experience

N Plevris; TA Manship; A Deekae; GR Jones; CL Noble; J Satsangi; AG Shand; ID Arnott; CW Lees

doi:10.1136/gutjnl-2017-314472.498

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via BSG

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

About
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens
Log in via BSG

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals More

Alerts

Inflammatory Bowel Disease

PTH-099 A novel approach to the implementation of biosimilar infliximab ct-p13 for the treatment of ibd utilising therapeutic drug monitoring: the edinburgh experience

Log in using your username and password

Main menu

Log in using your username and password

You are here

Read the full text or download the PDF:

Log in using your username and password